Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 18;13(6):1370.
doi: 10.3390/cancers13061370.

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy

Mirjam de With  1   2 , Daan P Hurkmans  1   3 , Esther Oomen-de Hoop  1 , Ayoub Lalouti  1 , Sander Bins  1 , Samira El Bouazzaoui  2 , Mandy van Brakel  1 , Reno Debets  1 , Joachim G J V Aerts  3 , Ron H N van Schaik  2 , Ron H J Mathijssen  1 , Astrid A M van der Veldt  1   4
Affiliations

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy

Mirjam de With et al. Cancers (Basel). .

Abstract

A substantial number of melanoma patients do not benefit from therapy with anti-PD-1. Therefore, we investigated the predictive value of single nucleotide polymorphisms (SNPs) in genes related to the PD-1 axis in patients with metastatic melanoma. From 119 consecutive melanoma patients who were treated with pembrolizumab or nivolumab monotherapy, blood samples were genotyped for 11 SNPs in nine genes. Associations between SNPs and OS were tested using Cox regression analysis and internally validated by bootstrapping. For SNPs with a statistical significance, an expression quantitative trait loci (eQTL) analysis was performed. In a subset of patients, immunophenotyping was performed. Patients with a SNP in PDCD1 (804C > T; rs2227981) had a significantly poorer OS with a 3-year OS rate of 51.8%, as compared to 71% in wild type patients (hazard ratio [HR] 2.37; 95% CI: 1.11-5.04; p = 0.026). eQTL analysis showed that this SNP was associated with decreased gene expression. In addition, PDCD1 804C > T carriers had a reduced fraction of peripheral PD-1+CD4+ T cells. No other associations between SNPs and OS were found. PDCD1 804C > T is associated with poorer OS after anti-PD-1 monotherapy in patients with metastatic melanoma. This SNP may affect clinical benefit from ICIs by decreasing transcription initiation and expression of PD-1 in T cells.

Keywords: PD-1; autoimmunity; germline variation; immune checkpoint inhibitors; metastatic melanoma.

PubMed Disclaimer

Conflict of interest statement

Astrid van der Veldt has received consultancy fees (paid to the institution) from at BMS, MSD, Merck, Ipsen, Eisai, Sanofi, Pierre Fabre, Pfizer, Novartis and Roche. Ron Mathijssen has received investigator-initiated research grants from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Pamgene, Pfizer, Novartis, Roche and Servier. Joachim Aerts has received personal fees from MSD, BMS, Boehringer-Ingelheim, Amphera, Eli-Lilly, Takeda, Bayer, Roche and Astra Zeneca. Reno Debets has received research grants from Merck, and travel expenses and consultancy fees from Genticel and Bluebird bio. All remaining authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Figures

Figure 1
Figure 1
Programmed cell death 1 (PD-1) expression in peripheral T cell populations according to PDCD1 804C > T genotypes. PD-1 expression in peripheral (A–C) CD4+ and (D–F) CD8+ T cells according to PDCD1 804C > T genotypes (comparing wild types (WT) and heterozygous variants + homozygous variants (VAR)). Peripheral T cells were collected prior to (baseline, graphs on the left) and during anti-PD-1 monotherapy (mid: prior to the second administration of anti-PD-1 monotherapy; right: prior to the third administration of anti-PD-1 monotherapy) in patients with metastatic melanoma (N = 47).
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Nathanson L. Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features, and possible mechanisms. Natl. Cancer Inst. Monogr. 1976;44:67–76. - PubMed
    1. Ronan S.G., Eng A.M., Briele H.A., Shioura N.N., Das Gupta T.K. Thin malignant melanomas with regression and metastases. Arch. Dermatol. 1987;123:1326–1330. doi: 10.1001/archderm.1987.01660340088026. - DOI - PubMed
    1. McGovern V.J., Shaw H.M., Milton G.W. Prognosis in patients with thin malignant melanoma: Influence of regression. Histopathology. 1983;7:673–680. doi: 10.1111/j.1365-2559.1983.tb02279.x. - DOI - PubMed
    1. Teulings H.E., Limpens J., Jansen S.N., Zwinderman A.H., Reitsma J.B., Spuls P.I., Luiten R.M. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis. J. Clin. Oncol. 2015;33:773–781. doi: 10.1200/JCO.2014.57.4756. - DOI - PubMed

LinkOut - more resources